Twist Bioscience Stock: 6 Straight Red Days, Down 19%
A steady string of losses for the biotech stock invites a closer look at a business whose growth comes at a significant cost.
Shares of Twist Bioscience (TWST) have now moved lower for 6 consecutive trading days, a slide that has cut 19% from the stock’s price. The decline has erased about $1.8 billion from the company’s market value, which now stands at about $7.8 billion.
For shareholders, this marks a sharp turn after a period of significant gains. Even with this recent drop, the stock has returned +80.2% over the trailing three months.
The Streak Next To The S&P 500
Here is how TWST stock stacks up against the S&P 500 over the streak and the periods around it:
| Return Period | TWST | S&P 500 |
|---|---|---|
| 1D | -3.1% | -0.4% |
| 6D (Current Streak) | -18.5% | -0.2% |
| 1M (21D) | 14.3% | 0.1% |
| 3M (63D) | 80.2% | 4.5% |
| YTD 2026 | 293.2% | 12.8% |
| 2025 | -31.7% | 16.4% |
| 2024 | 26.1% | 23.3% |
| 2023 | 54.8% | 24.2% |
What do the fundamentals say about this pressure?
The selling appears to be specific to Twist Bioscience. Over the same 6 trading days, the S&P 500 returned -0.2%. The company’s financial profile is mixed, showing rapid expansion alongside deep operational losses. Revenue over the last twelve months grew 19.2%, ahead of the S&P 500 median of 8.4%.
However, the company’s operating margin over the last twelve months is -32.0%, in stark contrast to an S&P 500 median of 18.6%. Twist Bioscience also has negative trailing earnings, meaning it does not have a meaningful price-to-earnings multiple.
A streak is information, not an instruction.
A multi-day move in either direction is a signal of focused market attention and momentum. It is not, by itself, a reason to buy or sell. The disciplined response is to use the moment to check the business against the price.
The data here offers a starting point for that work. A streak forces an investor to ask whether the market’s recent judgment aligns with the underlying financial reality of the company.
If the drop has you weighing an entry, resist buying a falling price alone. Our Buy the Dip screen ranks the marked-down names where growth and cash generation still support a recovery.
And for anyone who would rather back the theme than one company’s story, a biotech ETF like XBI holds the sector rather than this one name. It is still a concentrated bet on that one theme, though, which is exactly the gap the portfolio below closes.
Weakness In One Name Should Be Noise, Not News
For a diversified holder, a streak like this is a data point. For a concentrated one, it is a hole in the plan. The difference is never the stock; it is the portfolio built around it.
Building that portfolio is what the Trefis High Quality (HQ) Portfolio does: roughly 30 businesses with the cash generation and balance-sheet strength to absorb a bad month, selected and rebalanced by rules. It has a track record of outpacing a benchmark that combines the three major indices – the S&P 500, S&P Mid-cap, and Russell 2000. Make the next streak, in either direction, someone else’s drama.